Literature DB >> 30381409

Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques.

Florie Borel1,2, Gwladys Gernoux1, Huaming Sun1, Rachel Stock1, Meghan Blackwood1, Robert H Brown3, Christian Mueller4,5.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease caused by degeneration of motor neurons leading to rapidly progressive paralysis. About 10% of cases are caused by gain-of-function mutations that are transmitted as dominant traits. A potential therapy for these cases is to suppress the expression of the mutant gene. Here, we investigated silencing of SOD1, a gene commonly mutated in familial ALS, using an adeno-associated virus (AAV) encoding an artificial microRNA (miRNA) that targeted SOD1 In a superoxide dismutase 1 (SOD1)-mediated mouse model of ALS, we have previously demonstrated that SOD1 silencing delayed disease onset, increased survival time, and reduced muscle loss and motor and respiratory impairments. Here, we describe the preclinical characterization of this approach in cynomolgus macaques (Macaca fascicularis) using an AAV serotype for delivery that has been shown to be safe in clinical trials. We optimized AAV delivery to the spinal cord by preimplantation of a catheter and placement of the subject with head down at 30° during intrathecal infusion. We compared different promoters for the expression of artificial miRNAs directed against mutant SOD1 Results demonstrated efficient delivery and effective silencing of the SOD1 gene in motor neurons. These results support the notion that gene therapy with an artificial miRNA targeting SOD1 is safe and merits further development for the treatment of mutant SOD1-linked ALS.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30381409     DOI: 10.1126/scitranslmed.aau6414

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  23 in total

1.  Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy.

Authors:  Umut Cagin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Effective and Accurate Gene Silencing by a Recombinant AAV-Compatible MicroRNA Scaffold.

Authors:  Jun Xie; Phillip W L Tai; Alexander Brown; Shoufang Gong; Sha Zhu; Yi Wang; Chengjian Li; Cansu Colpan; Qin Su; Ran He; Hong Ma; Jia Li; Hanqing Ye; Jihye Ko; Phillip D Zamore; Guangping Gao
Journal:  Mol Ther       Date:  2019-11-27       Impact factor: 11.454

3.  Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?

Authors:  Allison M Keeler; Terence R Flotte
Journal:  Annu Rev Virol       Date:  2019-07-05       Impact factor: 10.431

4.  Nonnative structure in a peptide model of the unfolded state of superoxide dismutase 1 (SOD1): Implications for ALS-linked aggregation.

Authors:  Noah R Cohen; Jill A Zitzewitz; Osman Bilsel; C Robert Matthews
Journal:  J Biol Chem       Date:  2019-07-24       Impact factor: 5.157

5.  Treatment of a Mouse Model of ALS by In Vivo Base Editing.

Authors:  Colin K W Lim; Michael Gapinske; Alexandra K Brooks; Wendy S Woods; Jackson E Powell; M Alejandra Zeballos C; Jackson Winter; Pablo Perez-Pinera; Thomas Gaj
Journal:  Mol Ther       Date:  2020-01-14       Impact factor: 11.454

6.  SOD1 deficiency: a novel syndrome distinct from amyotrophic lateral sclerosis.

Authors:  Julien H Park; Christiane Elpers; Janine Reunert; Michael L McCormick; Julia Mohr; Saskia Biskup; Oliver Schwartz; Stephan Rust; Marianne Grüneberg; Anja Seelhöfer; Ulrike Schara; Eugen Boltshauser; Douglas R Spitz; Thorsten Marquardt
Journal:  Brain       Date:  2019-08-01       Impact factor: 13.501

Review 7.  Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases.

Authors:  Julia Doroszkiewicz; Magdalena Groblewska; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

Review 8.  Gene therapy for ALS: A review.

Authors:  Defne A Amado; Beverly L Davidson
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

Review 9.  Connecting RNA-Modifying Similarities of TDP-43, FUS, and SOD1 with MicroRNA Dysregulation Amidst A Renewed Network Perspective of Amyotrophic Lateral Sclerosis Proteinopathy.

Authors:  Jade Pham; Matt Keon; Samuel Brennan; Nitin Saksena
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

Review 10.  Stem Cell Models and Gene Targeting for Human Motor Neuron Diseases.

Authors:  Yashashree Karpe; Zhenyu Chen; Xue-Jun Li
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.